Roivant Sciences Ltd
F:87S

Watchlist Manager
Roivant Sciences Ltd Logo
Roivant Sciences Ltd
F:87S
Watchlist
Price: 12.51 EUR -1.73% Market Closed
Market Cap: 9.2B EUR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

87S Price Targets Summary
Roivant Sciences Ltd

Wall Street analysts forecast 87S stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 87S is 16.18 EUR with a low forecast of 10.06 EUR and a high forecast of 34.86 EUR.

87S Lowest Forecast
Wall Street Target
10.06 EUR
20% Downside
87S Average Forecast
Wall Street Target
16.18 EUR
29% Upside
87S Highest Forecast
Wall Street Target
34.86 EUR
179% Upside
Lowest
Price Target
10.06 EUR
20% Downside
Average
Price Target
16.18 EUR
29% Upside
Highest
Price Target
34.86 EUR
179% Upside
Roivant Sciences Ltd Competitors:
Price Targets
PRQR
ProQR Therapeutics NV
325% Upside
VRTX
Vertex Pharmaceuticals Inc
28% Upside
RAPT
Rapt Therapeutics Inc
22% Upside
CANTA
Cantargia AB
151% Upside
PRQR
ProQR Therapeutics NV
325% Upside
VRTX
Vertex Pharmaceuticals Inc
28% Upside
RAPT
Rapt Therapeutics Inc
22% Upside
CANTA
Cantargia AB
151% Upside
AMGN
Amgen Inc
12% Upside
ACAD
ACADIA Pharmaceuticals Inc
25% Upside
302440
SK Bioscience Co Ltd
13% Downside
BCYC
Bicycle Therapeutics PLC
249% Upside

Revenue
Forecast

Revenue Estimate
Roivant Sciences Ltd

For the last 4 years the compound annual growth rate for Roivant Sciences Ltd's revenue is 5%. The projected CAGR for the next 3 years is 170%.

5%
Past Growth
170%
Estimated Growth
Estimates Accuracy
-39%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Roivant Sciences Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
7%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Roivant Sciences Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-13%
Average Miss
What are analyst estimates?

See Also

Summary
87S intrinsic value, competitors valuation, and company profile.
DCF Valuation
87S stock valuation using Discount Cash Flow valuation method.
Relative Valuation
87S stock valuation using valuation multiples.
Wall Street Estimates
87S price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
87S stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 87S's stock price target?
Price Target
16.18 EUR

According to Wall Street analysts, the average 1-year price target for 87S is 16.18 EUR with a low forecast of 10.06 EUR and a high forecast of 34.86 EUR.

What is Roivant Sciences Ltd's Revenue forecast?
Projected CAGR
170%

For the last 4 years the compound annual growth rate for Roivant Sciences Ltd's revenue is 5%. The projected CAGR for the next 3 years is 170%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 284,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.